APC-2059
APC-2059 had been in phase II clinical trials for the treatment of inflammatory bowel diseases and ulcerative colitis. However, this study has been discontinued.
The compound was codeveloped by Celera and Bayer.
General Information
Update Date：2016-02-03
- Drug Name：
- APC-2059
- Research Code：
- APC-2059; CRA-2059
- Trade Name：
- MOA：
- Tryptase inhibitor
- Indication：
- Ulcerative colitis; Inflammatory bowel disease
- Status：
- Phase II (Discontinued)
- Company：
- Celera (Originator) , Bayer
- Sales：
- ATC Code：
Chemical Structure
Update Date：2016-02-01
|
Molecular Weight | 664.76 | ||||||||||||
| Formula | C34H46N12O8 | |||||||||||||
| CAS No. | 1356458-66-6 (APC-2059); | |||||||||||||
| Chemical Name | D-Mannitol, 1,4:3,6-dianhydro-, 2,5-bis[4-[[4-[(aminoiminomethyl)amino]phenyl]methyl]-1-piperazinecarboxylate] | |||||||||||||
| APC-2059 （Free Acid/Base）Parameters： | ||||||||||||||
|
||||||||||||||
| *：Calculated by ACD/Labs software V11.02. | ||||||||||||||